Related Experiment Video
Updated: Jun 24, 2026
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
A hepatitis C virus xenograft mouse efficacy model
1HCV Vaccine Research, Novartis Vaccines and Diagnostics, Emeryville, CA, USA.
Abstract:
The lack of a robust small-animal model for hepatitis C virus (HCV) has hindered the discovery and development of novel drug treatments for HCV infections. We developed a reproducible and easily accessible xenograft mouse efficacy model in which HCV RNA replication is accurately monitored in vivo by real-time, noninvasive, whole-body imaging of gamma-irradiated SCID mice implanted with a mouse-adapted luciferase replicon-containing Huh-7 cell line. The model has been validated by demonstrating that both a small molecule NS3/4A protease inhibitor (BILN 2061) and human interferon- alpha (IFN-alpha) decreased HCV RNA replication and that treatment withdrawal resulted in a rebound in replication, which paralleled clinical outcomes in humans. The efficacy of protease inhibitor plus IFN-alpha demonstrated the application of the model for testing compounds in combination therapies. This robust mouse efficacy model provides a powerful tool for rapid evaluation of potential anti-HCV compounds in vivo.
Insights
Researchers developed a new mouse model for studying hepatitis C virus (HCV) replication. This model accurately tracks HCV RNA and helps evaluate potential antiviral drugs, accelerating new treatment discovery.
Area of Science:
- Virology
- Drug Discovery
- Animal Models
Background:
- Hepatitis C virus (HCV) infection lacks effective small-animal models, impeding drug development.
- Current limitations hinder the discovery of novel therapeutics for HCV.
Purpose of the Study:
- To develop and validate a reproducible xenograft mouse efficacy model for studying HCV RNA replication in vivo.
- To enable noninvasive, real-time monitoring of HCV RNA replication using whole-body imaging.
Main Methods:
- Developed a xenograft mouse model using gamma-irradiated SCID mice implanted with Huh-7 cells containing a mouse-adapted luciferase replicon.
- Utilized real-time, noninvasive, whole-body imaging to monitor HCV RNA replication in vivo.
- Validated the model using a protease inhibitor (BILN 2061) and interferon-alpha (IFN-alpha).
Main Results:
- The model accurately monitored HCV RNA replication in vivo.
- Treatment with BILN 2061 and IFN-alpha significantly decreased HCV RNA replication.
- Withdrawal of treatment led to a rebound in viral replication, mirroring clinical outcomes.
- The model demonstrated efficacy in testing combination therapies.
Conclusions:
- This robust xenograft mouse model provides a powerful tool for evaluating anti-HCV compounds.
- The model facilitates the rapid in vivo assessment of potential drug candidates for HCV infections.
- It aids in accelerating the discovery and development of novel HCV treatments.
